Bu-Yi-Xin-Shen formula targets monocytes through PI3K-Akt/NF-κB signaling in post-percutaneous coronary intervention angina.

ABSTRACT:

Background

Bu-Yi-Xin-Shen formula (BYXSF) is used for the treatment of post-percutaneous coronary intervention (PCI) angina. This study combined bioinformatics and experimental verification to investigate its mechanism of action.

Methods

We retrieved relevant target data from public databases to determine candidate therapeutic targets of BYXSF in post-PCI angina. Key targets were then determined using protein-protein interaction (PPI) network and functional enrichment assays. Molecular docking was used to identify core active ingredients, while toxicity evaluation helped assess their safety profiles. After that, single-cell RNA sequencing (scRNA-seq) uncovered critical cell types and the expression patterns of target genes. Finally, in vivo animal experiments provided

SUBMITTER: Su C 

PROVIDER: S-EPMC12808082 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature